EW - Edwards Lifesciences Non-GAAP EPS of $0.60 beats by $0.03 revenue of $1.34B beats by $30M

Edwards Lifesciences press release (NYSE:EW): Q1 Non-GAAP EPS of $0.60 beats by $0.03. Revenue of $1.34B (+9.8% Y/Y) beats by $30M. Q1 TAVR sales grew 11 percent; underlying 14 percent Overall, the company is reaffirming sales guidance for all product groups.  Full year 2022 sales are expected to grow at a low double-digit underlying rate to $5.5 to $6.0 billion, which includes an estimated negative year-over-year impact of $170 million from foreign exchange.  Additionally, the company continues to expect full year 2022 adjusted earnings per share of $2.50 to $2.65, representing mid-teens growth over 2021. For the second quarter of 2022, the company projects total sales to be between $1.36 and $1.44 billion, and adjusted EPS of $0.61 to $0.69.

For further details see:

Edwards Lifesciences Non-GAAP EPS of $0.60 beats by $0.03, revenue of $1.34B beats by $30M